Plasma total homocysteine: Instigator or indicator of cardiovascular disease?

Annals of Clinical Biochemistry

Volumn 45, Issue 4, 2008, Pages 345-348

  Moat, Stuart J ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FOLIC ACID; HOMOCYSTEINE; VITAMIN B GROUP;

AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CELL DESTRUCTION; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HOMOCYSTEINE BLOOD LEVEL; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; THROMBOGENESIS;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FOLIC ACID; HOMOCYSTEINE; HUMANS; INFLAMMATION; RISK FACTORS;

EID: 47749085079     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2008.008053     Document Type: Article

References (31)

1. McKully KS. Hyperhomocysteinaemia and arteriosclerosis: historical perspectives. Clin Chem Lab Med 2005;43:980-6
2. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998;5:229-32
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57
4. Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 1998;18:1895-901
5. Clarke R, Lewington S, Donald A, et al. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovascular Risk 2001;8:363-9
6. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005;82:806-12
7. Bønaa KH, Njølstad I, Ueland PM, et al., NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88
8. The Heart Outcomes Prevention Evaluation (HOPE) 2 investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-77
9. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75
10. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006;296:2720-26
11. Clarke R, Armitage J, Lewington S, Sherliker P, Collins R, on behalf of the B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention ofcardiovascular events:a reviewofthe design and power of the large randomized trials. Am Heart J 2006;151:282-7
12. Moat SJ, McDowell IFW. Homocysteine and endothelial function in human studies. Semin Vasc Med 2005;5:172-82
13. Doshi SN, McDowell IF, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002;105 :22-6
14. de Bree A, van Mierlo LA, Draijer R. Folic acid improves vascular reactivity in humans: a meta analysis of randomised controlled trials. Am J Clin Nutr 2007;86:610-7
15. Yap S, Boers GH, Wilcken B, et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 2001;21:2080-5
16. Turgan N, Habiff S, Parildar Z, et al. Association between homocysteine and neopterin in healthy subjects meaured by a simple HPLC-fluorometric method. Clin Biochem 2001;34:271-5
17. Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999;84:1018-22
18. Tatzber F, Rabl H, Koriska K, et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 1991;89:203-8
19. Ridker PM, Cushman M, Stampfer MJ, Tracy R, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9
20. Vanizor KB, Orem A, Cimsit G, Uydu HA, Yandi YE, Alver A. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003;332:23-30
21. Refai TM, Al Salem IH, Nkansa-Dwamena D, Al Salem MH. Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients. Clin Rheumatol 2002;21:457-61
22. Roubenoff R, Dellaripa P, Nadeau MR, et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 1997;40:718-22
23. Sun CF, Haven TR, Wu TL, Tsao KC, Wu JT. Serum total homocysteine increases with the rapid proliferation rate of tumor cells and decline upon cell death: a potential new tumor marker. Clin Chim Acta 2002;321:55- 62
24. Widner B, Leblhuber F, Frick B, Laich A, Artner-Dworzak E, Fuchs D. Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease. J Neural Trans 2002;109:1445-52
25. Lazzerini PE, Capecchi PL, Bisogno S, Galeazzi M, Marcolongo R, Pasini FL. Reduction in plasma homocysteine level in patients with rheumatoid arthritis given pulsed glucocorticoid treatment. Ann Rheum Dis 2003;62:694-5
26. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med 1995;237:381-8
27. Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995;26:795-800
28. Fuchs D, Jaeger M, Widner B, Wirleitner B, Artner-Dworzak E, Leblhuber F. Is hyperhomocysteinemia due to the oxidative depletion of folate rather than to insufficient dietary intake? Clin Chem Lab Med 2001;39:691-4
29. Moat SJ, Bonham JR, Tanner MS, Allen JC, Powers HJ. Recommended approaches for the laboratory measurement of homocysteine in the diagnosis and monitoring of patients with hyperhomocysteinaemia. Ann Clin Biochem 1999;6:372-9
30. Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32
31. Moat SJ, Doshi SN, Lang D, et al. Treatment of coronary heart disease with folic acid: is there a future? Am J Physiol Heart Circ Physiol 2004;287:H1-7